United States Government Publishing Office publisher pbl distributor dst United States Health and Human Services Department Food and Drug Administration author aut Government Organization text government publication eng CMR Executive Agency Publications executive 2025-07-14 Health and Human Services Department, Food and Drug Administration 2024-04-19 continuing Annual deposited born digital 79 digital object pages HE 20.4002:P 41/3/ https://www.govinfo.gov/app/details/CMR-HE20_4000-00195421 P0b002ee1d51e4cad 001455479 DGPO 2025-07-14 2025-07-14 CMR-HE20_4000-00195421 machine generated eng fdlp HE20_4000 CMR-HE20_4000-00195421 00195421 00195421 Department of Health and Human Services - Food and Drug Administration (FDA) Food and Drug Administration 2024-04-19 Committee-Subcommittee 2024-04-19 2025-07-11 2024-06-18 false HOUSE SENATE 118 21 U.S.C. 379j-53(a) Progress of the Food and Drug Administration in achieving the goals identified in the letters described in section 401(b) of the Biosimilar User Fee Amendments of 2022 during such fiscal year and the future plans of the Food and Drug Administration for meeting such goals Annually false false true 075 075 75 009 10 HHS 7500 HHS 7524 FDA Committee on Energy and Commerce Energy and Commerce Committee on Health, Education, Labor, and Pensions Health, Education, Labor, and Pensions

HE 20.4002:P 41/3/ United States Congress associated name asn https://www.govinfo.gov/content/pkg/CMR-HE20_4000-00195421 https://www.govinfo.gov/app/details/CMR-HE20_4000-00195421 https://www.govinfo.gov/content/pkg/CMR-HE20_4000-00195421/pdf/CMR-HE20_4000-00195421.pdf User charges and fees Performance Report to Congress: Biosimilar User Fee Act FY 2023 United States Congress House of Representatives Committee on Energy and Commerce associated name asn United States Congress Senate Committee on Health, Education, Labor, and Pensions associated name asn Title 21 Section 379j-53(a) 21 U.S.C. 379j-53(a)